Comments on post “Elysium Health”
Eric Marcotulli
@eric_marcotulli · Founder/CEO of Elysium Health
Eric Marcotulli, CEO of Elysium Health here. I appreciate the thoughts and ideas offered on this page, and I wanted to provide some of mine in return, as well as answer some of the questions that were outlined.
Efficacy + Clinical Data. Elysium’s mission is to solve the biggest challenges in health. That cannot be done without conducting rigorous clinical research and actually assuming the responsibility of pushing that research forward. In February 2016, we submitted to ClinicalTrials.gov the protocol for the first human study of our product Basis: – a placebo-controlled, double-blind, randomized study of 120 healthy individuals between the ages of 60 and 80. (The age bracket was chosen based upon the fact that these individuals would be the most depleted in their levels of NAD+, the critical coenzyme that declines as we age and is the target of Basis). We posted it not only because we wanted to demonstrate our dedication to a rigorously architected study, but because we are also committed to transparency.
We concluded the study a few months ago, and we have since analyzed the data and drafted a manuscript that we are submitting for the peer-review process – again, because we want to meet and exceed the standards typically found in our broader market. This past week, we announced the topline results of that study:
• In the bracketed age group, study participating taking our recommended dose of Basis saw an average increase in NAD+ levels of 40% in the first 30 days and kept that increase constant at 60 days. This equates to NAD+ levels those individuals would have had during their youth.
• The p value for this change was <0.01.
• The placebo group did not see a change at all.
• There were no material adverse events, and the product was well tolerated.
This is important in that, for the first time ever, it was demonstrated that a product, Basis, can safely increase and sustain NAD+ levels. The remainder of our findings and full study analysis will be published in the months ahead. I am happy to see such fervor regarding the need for these studies, and you will see more of them related to Basis and our pipeline products. In fact, a significant amount of our recently announced funding will go toward clinical research conducted at top tier institutions and focused on high-severity areas in human health.
3sharetweet・